Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Amyloid beta (Abeta) immunoreactivity in neurons was examined in brains of 32 control subjects, 31 people with Down syndrome, and 36 patients with sporadic Alzheimer's disease to determine if intraneuronal Abeta immunoreactivity is an early manifestation of Alzheimer-type pathology leading to fibrillar plaque formation and/or neurofibrillary degeneration. The appearance of Abeta immunoreactivity in neurons in infants and stable neuron-type specific Abeta immunoreactivity in a majority of brain structures during late childhood, adulthood, and normal aging does not support this hypothesis. The absence or detection of only traces of reaction with antibodies against 4-13 aa and 8-17 aa of Abeta in neurons indicated that intraneuronal Abeta was mainly a product of alpha- and gamma-secretases (Abeta(17-40/42)). The presence of N-terminally truncated Abeta(17-40) and Abeta(17-42) in the control brains was confirmed by Western blotting and the identity of Abeta(17-40) was confirmed by mass spectrometry. The prevalence of products of alpha- and gamma -secretases in neurons and beta- and gamma-secretases in plaques argues against major contribution of Abeta-immunopositive material detected in neuronal soma to amyloid deposit in plaques. The strongest intraneuronal Abeta(17-42) immunoreactivity was observed in structures with low susceptibility to fibrillar Abeta deposition, neurofibrillary degeneration, and neuronal loss compared to areas more vulnerable to Alzheimer-type pathology. These observations indicate that the intraneuronal Abeta immunoreactivity detected in this study is not a predictor of brain amyloidosis or neurofibrillary degeneration. The constant level of Abeta immunoreactivity in structures free from neuronal pathology during essentially the entire life span suggests that intraneuronal amino-terminally truncated Abeta represents a product of normal neuronal metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921 · cited 1×
“Cells may produce and secrete several species of A, including A 1–40 , A 1–42/3 and A 17–40/42 [8, 23 , 24].”
BackgroundIntraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830
Takahashi, R. H., Milner, T. A., Li, F., Nam, E. E., Edgar, M. A., Yamaguchi, H., Beal, M. F., Xu, H., Greengard, P., & Gouras, G. K. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64463-x · Cited by 706
Saido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, Y., & Kawashima, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90301-1 · Cited by 587
Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584 · cited 1×
“Overexpression of APP, overproduction of A, and early intracellular accumulation of A [ 33 ] have been considered the foundation for early onset of AD pathology and functional deterioration in adults with Down syndrome (DS) in their 40’s [22, 39, 63].”
BackgroundSelf-citationGeneration of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells.
Busciglio, J., Gabuzda, D. H., Matsudaira, P., & Yankner, B. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.2092 · Cited by 569
Research works printed but not linked: 46
- Allsop D, Haga S, Bruton C, Ishii T, Roberts GW (1990) Neurofibrillary tangles in some cases of dementia pugilistica share antigens with amyloid beta protein of Alzheimer’s disease. Am J Pathol 136:255–260
- Bahr BA, Hoffman KB, Yang AJ, Hess US, Glabe CG, Lynch G (1998) Amyloid β-protein is internalized selectively by hippocampal field CA1 and neurons to accumulate amyloidogenic carboxyterminal fragments of the amyloid precursor protein. J Comp Neurol 397:139–147 · DOI · Paper page
- Bancher C, Grundke-Iqbal I, Kim KS, Wisniewski HM (1989) Immunoreactivity of neuronal lipofuscin, with monoclonal antibodies to the amyloid β-protein. Neurobiol Aging 10:125–132 · DOI
- Braak H, Braak E (1995) Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging 16:271–284 · DOI · Paper page
- Cook DG, Forman MS, Sung JC, Leight S, Kolson DL, Iwatsubo T, Lee VM, Doms RW (1997) Alzheimer’s Aβ (1–42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med 3:1021–1023 · DOI · Paper page
- Frackowiak J, Zoltowska A, Wisniewski H (1994) Non-fibrillar β-amyloid protein is associated with smooth muscle cells of vessel wlls in Alzheimer disease. J Neuropathol Exp Neurol 53:637–645 · DOI · Paper page
- Frackowiak J, Miller DL, Potempska A, Sukontasup T, Mazur-Kolecka B (2003) Secretion and accumulation of Aβ by brain vascular smooth muscle cells from AβPP-Swedish transgenic mice. J Neuropathol Exp Neurol 62:685–696 · DOI · Paper page
- Frackowiak J, Sukontasup T, Potempska A, Mazur-Kolecka B (2004) Lysosomal deposition of Aβ in cultures of brain vascular smooth muscle cells is enhanced by iron. Brain Res 1002:67–75 · DOI
- Goedert M, Spillantini M, Jakes R, Rutherford D, Crowther R (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 3:519–526 · DOI · Paper page
- Guiroy DC, Mellini M, Miyazaki M, Hilbich C, Safar J, Garruto RM, Yanagihara R, Beyreuther K, Gajdusek DC (1993) Neurofibrillary tangles of Guamanian amyotrophic lateral sclerosis, parkinsonism dementia, and neuropathologically normal Guamanians contain a 4–4.5 kDa protein which is immunorective to anti-amyloid beta/A4 protein antibodies. Acta Neuropathol 86:265–274 · doi:10.1007/bf00304141
- Haass C, Hung AY, Schlossmacher MG, Teplow DB, Selkoe DJ (1993) β-amyloid peptide and 3 kDa fragment are derived by distinct cellular mechanisms. J Biol Chem 268:3021–3024 · DOI · Paper page
- Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL, Dotti CG, Unsicker K, Beyreuther K (1997) Distinct sites of intracellular production for Alzheimer’s disease Aβ40/42 amyloid peptides. Nat Med 3:1016–1020 · DOI · Paper page
- Hyman BT, Van Hoesen GW, Beyreuther K, Masters CL (1989) A4 amyloid protein immunoreactivity is present in Alzheimer’s disease neurofibrillary tangles. Neurosci Lett 101:352–355 · DOI
- Ito H, Hirano A, Yen S-H, Katao S (1991) Demonstration of β amyloid protein containing neurofibrillary tangles in parkinsonism-dementia complex of Guam. Neuropathol Appl Neurobiol 17:365–373 · DOI
- Iqbal K, Braak H, Braak E, Grundke-Iqbal I (1993) Silver labeling of Alzheimer neurofibrillary changes and brain β-amyloid. J Histotech 16:335–342 · DOI · Paper page
- Kim KS, Miller DL, Sapienza VJ, Chen CMJ, Bai C, Grundke-Iqbal I, Currie J, Wisniewski HM (1988) Neurosci Res Commun 2:121–130
- Kim KS, Wen GY, Bancher C, Chen CMJ, Sapienza VJ, Hong H, Wisniewski HM (1990) Detection, quantitation of amyloid β-peptide with 2 monoclonal antibodies. Neurosci Res Comm 7:113–122
- Kitamoto T, Ogomori K, Tateishi J, Prusiner S (1987) Methods in laboratory investigation. Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest 57:230–236
- Kuchna I, Wegiel J, Tarnawski M, Badmaev E, Kozlowski P, Pirttila T, Kivimaki T, Lehtimaki T, Visser F, Devenny D, Silverman W (2001) Alzheimer type pathology in the memory system of people with Down syndrome. J Neuropathol Exp Neurol 60:545
- Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K (1985) Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer’s disease contain the same protein as the amyloid plaque cores and blood vessels. EMBO J 4:2757–2763 · DOI · Paper page
- McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 46:860–866 · doi:10.1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m
- Miller DL, Currie JR, Mehta PD, Potempska A, Hwang Yu-Wen, Wegiel J (2003) Humoral immune response to fibrillar β-amyloid peptide. Biochemistry 42:11682–11692 · DOI
- Miller DL, Potempska A, Mehta PD (2007) Humoral immune responses to peptides derived from the β-amyloid peptide C-terminal sequence. Amyloid (in press) · DOI
- Murphy GM, Forno LS, Higgins L, Scardina JM, Eng LF, Cordell B (1994) Development of monoclonal antibody specific for the COOH-terminal of Aβ-amyloid 1–42 and its immunohistochemical reactivity in Alzheimer’s disease and related disorders. Am J Pathol 144:1082–1088
- Payan IL, Chou S-J, Fisher GH, Man EH, Emory C, Frey WH (1992) Altered aspartate in Alzheimer neurofibrillary tangles. Neurochem Res 17:187–191 · DOI
- Perry G, Cras P, Siedlak SL, Tabaton M, Kawai M (1992) β protein immunoreactivity is found in the majority of neurofibrillary tangles of Alzheimer’s disease. Am J Pathol 140:283–290
- Pike CJ, Overman MJ, Cotman CW (1995) Amino-terminal deletions enhance aggregation of β-amyloid peptides in vitro. J Biol Chem 270:23895–23898 · DOI · Paper page
- Potempska A, Mack K, Mehta P, Kim KS, Miller DL (1999) Quantification of sub-femtomole amount of Alzheimer amyloid β peptides. Amyloid 6:14–21 · DOI · Paper page
- Reisberg B, Ferris SH, DeLeon MJ, Crook T (1982) The global deterioration scale for the assessment of promary degenerative dementia. Am J Psychol 139:1136–1139 · DOI · Paper page
- Reisberg B (1988) Functional assessment staging (FAST). Psychopharmacol Bull 24:653–659
- Rosenblum WI (1999) The presence, origin, and significance of Aβ peptide in the cell bodies of neurons. J Neuropathol Exp Neurol 58:575–581 · DOI
- Schwab C, Akiyama H, McGeer EG, McGeer PL (1998) Extracellular neurofibrillary tangles are immunopositive for the 40 carboxy-terminal sequence of β-amyloid protein. J Neuropathol Exp Neurol 57:1131–1137 · DOI
- Schweers O, Schonbrunn-Hanebeck E, Marx A, Mandelkow E (1994) Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta structure. J Biol Chem 269:24290–24297 · DOI · Paper page
- Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C, Wattez A, David J-P, Vanmechelen E, Sergheraert C, Delacourte A (2003) Truncated beta-amyloid peptide species in pre-clinical Alzheimer’s disease as new targets for the vaccination approach. J Neurochem 85:1581–1591 · DOI · Paper page
- Shapira R, Austin GE, Mirra SS (1988) Neuritic plaque amyloid is highly racemized. J Neurochem 50:69–74 · DOI · Paper page
- Sokol DK, Chen D, Farlow MR, Dunn DW, Maloney B, Zimmer JA, Lahiri DK (2006) High levels of Alzheimer beta- amyloid precursor protein (APP) in children with severely autistic behavior and aggression. J Child Neurol 21:444–449 · DOI · Paper page
- Stern RA, Otvos L Jr, Trojanowski JQ, Lee VM (1989) Monoclonal antibodies to a synthetic peptide homologous with the first 28 amino acids of Alzheimer’s diease beta-protein recognize amyloid and diverse glial and neuronal cell types in the central nervous system. Am J Pathol 134:973–978
- Tabaton M, Cammarata S, Mancardi G, Manetto V, Autilio-Gambetti L, Perry G, Gambetti P (1991) Ultrastructural localization of β-amyloid, tau and ubiquitin epitopes in extracellular neurofibrillary tangles. Proc Natl Acad Sci USA 88:2098–2102 · DOI · Paper page
- Takahashi RH, Nam EE, Edgar M, Gouras GK (2002) Alzheimer β-amyloid peptides: normal and abnormal localization. Histol Histopathol 17:239–246
- Wang R, Sweeney D, Gandy SE, Sisodia S (1996) The profile of soluble amyloid β protein in cultured media. J Biol Chem 271:31894–31902 · DOI · Paper page
- Wegiel J, Wisniewski HM, Morys J, Tarnawski M, Kuchna I, Dziewiatkowski J, Pirttilä T, Krivimäki T, Lehtimäki T, Lach B (1999) Neuronal loss and amyloid-β removal in the amygdala of people with Down syndrome. Neurobiol Aging 20:259–269 · DOI
- Wegiel J, Kuchna I, Miller D, Mehta P, Wegiel J, Wisniewski T, Reisberg B, Silverman W (2002) Intraneuronal accumulation of N-terminally truncated amyloid beta. J Neuropathol Exp Neurol 61:483
- Wilson CA, Doms RW, Lee VM-Y (1999) Intracellular APP processing and Aβ production in Alzheimer disease. J Neuropathol Exp Neurol 58:787–794 · DOI · Paper page
- Wisniewski KE, Maslinska D, Kitaguchi T, Kim KS, Goebel HH, Haltia M (1990) Topographic heterogeneity of amyloid β-protein epitopes in brains with various forms of neuronal lipofuscinoses suggesting defective processing of amyloid precursor protein. Acta Neuropathol 80:26–34 · DOI
- Xu H, Sweeney D, Wang R, Thinakaran G, Lo ACY, Sisodia SS, Greengard P, Gandy S (1997) Generation of Alzheimer’s β-amyloid protein in the trans-Golgi in the apparent absence of vesicle formation. Proc Natl Acad Sci USA 94:3748–3752 · DOI · Paper page
- Yamaguchi H, Nakazato Y, Shoji M, Okamoto K, Ihara Y, Morimatsu M, Hirai S (1991) Secondary deposition of beta amyloid within extracellular neurofibrillary tangles in Alzheimer-type dementia. Am J Pathol 138:699–705
Cited by
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Classification and basic pathology of Alzheimer disease
Duyckaerts, C., Delatour, B., & Potier, M.-C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0532-1 · Cited by 1,031
Antonarakis, S. E., Skotko, B. G., Rafii, M. S., Strydom, A., Pape, S. E., Bianchi, D. W., Sherman, S. L., & Reeves, R. H. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0143-7 · Cited by 964
An overview of APP processing enzymes and products.
Chow, V. W., Mattson, M. P., Wong, P. C., & Gleichmann, M. (2010) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8104-z · Cited by 684
A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome
Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L. J., Fisher, E. M. C., & Strydom, A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3983 · Cited by 562
Metadata
- Authors
- Wegiel, J., Kuchna, I., Nowicki, K., Frackowiak, J., Mazur-Kolecka, B., Imaki, H., Wegiel, J., Mehta, P. D., Silverman, W. P., Reisberg, B., deLeon, M., Wisniewski, T., Pirttilla, T., Frey, H., Lehtimäki, T., Kivimäki, T., Visser, F. E., Kamphorst, W., Potempska, A., Bolton, D., Currie, J. R., & Miller, D. L.
- Venue
- Acta Neuropathologica
- Published
- 2007-01-20
- Volume
- 113
- Issue
- 4
- Pages
- 389-402
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2127714088
- Cited by
- 92
- References
- 22
- FWCI
- 6.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by-nc/2.0 (tdm)
- creativecommons.org/licenses/by-nc/2.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration. https://app.cochat.ai/papers/10.1007/s00401-006-0191-4
- The paper
- Wegiel, J., Kuchna, I., Nowicki, K., Frackowiak, J., Mazur-Kolecka, B., Imaki, H., Wegiel, J., Mehta, P. D., Silverman, W. P., Reisberg, B., deLeon, M., Wisniewski, T., Pirttilla, T., Frey, H., Lehtimäki, T., Kivimäki, T., Visser, F. E., Kamphorst, W., Potempska, A., . . . Miller, D. L. (2007). Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration. Acta Neuropathologica. https://doi.org/10.1007/s00401-006-0191-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.